On January 26, 2021 Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY; the "Company")reported that successfully completed the placement of the subordinated mandatory convertible notes, which the Company’s Executive Board resolved to issue with the approval of the Supervisory Board on January 7, 2021 (Press release, Epigenomics, JAN 26, 2021, View Source [SID1234574338]). In total, the mandatory convertible bond in the nominal amount of EUR 5,500,000.00 was fully placed. The offering was significantly oversubscribed. The mandatory convertible bond consists of 500,000 bonds, which are convertible into 5,000,000 registered shares of the Company. The gross proceeds from the issuance of the mandatory convertible bond amount to EUR 5.5 million.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!